Thompson Davis & Co’s Haemonetics HAE Stock Holding History

Thompson Davis & Co’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,250	Closed	-$256K	–	113
2022 Q4	$256K	Buy	+3,250	New	+$261K	0.36%	59

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thompson Davis & Co's HAE Position: Q1 2023 in Review

Thompson Davis & Co sold out of Haemonetics (HAE) in Q1 2023, closing a stake of 3,250 shares — an estimated $256K sold.

Thompson Davis & Co first reported a position in HAE in Q4 2022 and held it in 1 quarter. The position peaked at $256K in Q4 2022. 301 funds tracked by Wall St. Rank hold HAE as of Q1 2023.

Thompson Davis & Co reported no remaining Haemonetics position as of Q1 2023 after selling out during the quarter.
Thompson Davis & Co sold 3,250 Haemonetics shares in Q1 2023, an estimated $256K.
Thompson Davis & Co first reported a position in Haemonetics in Q4 2022 and held it in 1 quarter.
Thompson Davis & Co's Haemonetics position peaked at $256K in Q4 2022.
301 funds tracked by Wall St. Rank held Haemonetics as of Q1 2023.

Based on Thompson Davis & Co's 13F filing for Q1 2023, filed 10 May 2023.